{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:34:31Z","timestamp":1762508071182,"version":"build-2065373602"},"reference-count":44,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progr\u00e8s en Urologie"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.purol.2020.03.005","type":"journal-article","created":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T17:09:16Z","timestamp":1586452156000},"page":"322-331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["The role of device-assisted therapies in the management of non-muscle invasive bladder cancer: A systematic review"],"prefix":"10.1016","volume":"30","author":[{"given":"R.","family":"Carando","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Pradere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Afferi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Marra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Roghmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Krajewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Di Bona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Alvarez-Maestro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Pagliarulo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Xylinas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.purol.2020.03.005_bib0225","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.purol.2020.03.005_bib0230","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0022-5347(05)67972-4","article-title":"Tumour progression and survival of patients with high grade, non-invasive papillary (TaG3) bladder tumors: 15-year outcome","volume":"163","author":"Herr","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2020.03.005_bib0235","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016","author":"Babjuk","year":"2016","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.purol.2020.03.005_bib0240","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.purol.2020.03.005_bib0245","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol"},{"issue":"11","key":"10.1016\/j.purol.2020.03.005_bib0250","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1093\/annonc\/mdz296","article-title":"EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees\u2020","volume":"30","author":"Horwich","year":"2019","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.purol.2020.03.005_bib0255","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.eururo.2019.09.035","article-title":"EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multistakeholder effort\u2020: under the auspices of the EAU-ESMO guidelines committees","volume":"77","author":"Witjes","year":"2020","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.purol.2020.03.005_bib0260","doi-asserted-by":"crossref","first-page":"112","DOI":"10.5301\/RU.2013.11296","article-title":"Role of the combined regimen with local chemotherapy and Mw-induced hyperthermia for non-muscle invasive bladder cancer management. A systematic review","volume":"80","author":"Colombo","year":"2013","journal-title":"Urologia"},{"key":"10.1016\/j.purol.2020.03.005_bib0265","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.purol.2020.03.005_bib0270","doi-asserted-by":"crossref","first-page":"218","DOI":"10.20517\/2394-4722.2017.35","article-title":"Cancer immunity and therapy using hyperthermia with immunotherapy, radiotherapy, chemotherapy, and surgery","volume":"3","author":"Yagawa","year":"2017","journal-title":"J Cancer Metastasis Treat"},{"issue":"4","key":"10.1016\/j.purol.2020.03.005_bib0275","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3109\/02656736.2016.1157903","article-title":"A systematic review of regional hyperthermia therapy in bladder cancer","volume":"32","author":"Longo","year":"2016","journal-title":"Int J Hyperthermia"},{"key":"10.1016\/j.purol.2020.03.005_bib0280","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.semcancer.2016.03.004","article-title":"Effects of hyperthermia as a mitigation strategy in DNA damage-based cancer therapies","volume":"37\u201338","author":"Mantso","year":"2016","journal-title":"Semin Cancer Biol"},{"issue":"4","key":"10.1016\/j.purol.2020.03.005_bib0285","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/jso.2930280412","article-title":"The effects of hyperthermia on vascular permeability in experimental liver metastasis","volume":"28","author":"Lefor","year":"1985","journal-title":"J Surg Oncol"},{"issue":"3","key":"10.1016\/j.purol.2020.03.005_bib0290","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/02656730500532028","article-title":"Cell biological effects of hyperthermia alone or combined with radiation or drugs: a short introduction to newcomers in the field","volume":"22","author":"Kampinga","year":"2006","journal-title":"Int J Hyperthermia"},{"issue":"4","key":"10.1016\/j.purol.2020.03.005_bib0295","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1097\/01.ju.0000146274.85012.e1","article-title":"Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study","volume":"173","author":"Vanderheijden","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2020.03.005_bib0300","first-page":"83","article-title":"Radiofrequency-induced thermo-chemotherapy effect (RITE) for non muscle invasive bladder cancer treatment: current role and perspectives","author":"Colombo","year":"2016","journal-title":"Urologia"},{"issue":"2","key":"10.1016\/j.purol.2020.03.005_bib0305","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1245\/ASO.2004.03.059","article-title":"Focused microwave phased array thermotherapy for ablation of early-stage breast cancer: results of thermal dose escalation","volume":"11","author":"Vargas","year":"2004","journal-title":"Ann Surg Oncol"},{"issue":"984","key":"10.1016\/j.purol.2020.03.005_bib0310","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1259\/bjr\/13217618","article-title":"Assessment of early treatment response after CT-guided radiofrequency ablation of unresectable lung tumours by diffusion-weighted MRI: a pilot study","volume":"82","author":"Okuma","year":"2009","journal-title":"Br J Radiol"},{"issue":"7","key":"10.1016\/j.purol.2020.03.005_bib0315","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1080\/02656736.2017.1406618","article-title":"Intravesical radiofrequency induced hyperthermia enhances mitomycin C accumulation in tumour tissue","volume":"34","author":"van Valenberg","year":"2018","journal-title":"Int J Hyperthermia"},{"issue":"3 Pt 2","key":"10.1016\/j.purol.2020.03.005_bib0320","first-page":"959","article-title":"A new approach using local combined microwave hyperthermia and chemotherapy in superficial transitional bladder carcinoma treatment","volume":"153","author":"Colombo","year":"1995","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.purol.2020.03.005_bib0325","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.eururo.2016.01.006","article-title":"Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus Bacillus Calmette-Gu\u00e9rin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer","volume":"69","author":"Arends","year":"2016","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.purol.2020.03.005_bib0330","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/j.1464-410X.2010.09654.x","article-title":"Long-term outcomes of a randomised controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC)","volume":"107","author":"Colombo","year":"2011","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.purol.2020.03.005_bib0335","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000435788","article-title":"Predictive factors for time to progression after hyperthermic mitomycin C treatment for high-risk non-muscle invasive urothelial carcinoma of the bladder: an observational cohort study of 97 patients","volume":"96","author":"Sooriakumaran","year":"2016","journal-title":"Urol Int"},{"issue":"8","key":"10.1016\/j.purol.2020.03.005_bib0340","first-page":"666","article-title":"Thermochemotherapy in adjuvant treatment of primary high risk non-muscle invasive bladder cancers: single centre results","volume":"68","author":"Erturhan","year":"2015","journal-title":"Arch Esp Urol"},{"issue":"5","key":"10.1016\/j.purol.2020.03.005_bib0345","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00280-014-2423-y","article-title":"Intravesical mitomycin C combined with local microwave hyperthermia in non-muscle-invasive bladder cancer with increased European Organisation for Research and Treatment of Cancer (EORTC) score risk of recurrence and progression","volume":"73","author":"Maffezzini","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"10.1016\/j.purol.2020.03.005_bib0350","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2217\/fon.12.90","article-title":"10-year single-center experience of combined intravesical chemohyperthermia for non-muscle invasive bladder cancer","volume":"8","author":"Moskovitz","year":"2012","journal-title":"Future Oncol"},{"issue":"3","key":"10.1016\/j.purol.2020.03.005_bib0355","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.urolonc.2009.02.012","article-title":"Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder","volume":"29","author":"Halachmi","year":"2011","journal-title":"Urol Oncol [Internet]"},{"issue":"1","key":"10.1016\/j.purol.2020.03.005_bib0360","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.eururo.2018.09.005","article-title":"Radiofrequency-induced thermo-chemotherapy effect versus a second course of Bacillus Calmette-Gu\u00e9rin or institutional standard in patients with recurrence of non-muscle-invasive bladder cancer following induction or maintenance Bacillus Calmette-Gu\u00e9rin Th","volume":"75","author":"Tan","year":"2019","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.purol.2020.03.005_bib0365","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000341912","article-title":"Thermochemotherapy for non-muscle-invasive bladder cancer: is there a chance to avoid early cystectomy?","volume":"89","author":"Volpe","year":"2012","journal-title":"Urol Int"},{"issue":"4","key":"10.1016\/j.purol.2020.03.005_bib0370","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.juro.2009.06.017","article-title":"Combined thermo-chemotherapy for recurrent bladder cancer after Bacillus Calmette-Guerin","volume":"182","author":"Nativ","year":"2009","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.purol.2020.03.005_bib0375","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00345-009-0384-2","article-title":"Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party","volume":"27","author":"Alfred Witjes","year":"2009","journal-title":"World J Urol"},{"issue":"2","key":"10.1016\/j.purol.2020.03.005_bib0380","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/iju.12639","article-title":"Is thermochemotherapy with the Synergo system a viable treatment option in patients with recurrent non-muscle-invasive bladder cancer?","volume":"22","author":"Kiss","year":"2015","journal-title":"Int J Urol"},{"issue":"4","key":"10.1016\/j.purol.2020.03.005_bib0385","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrurol.2015.58","article-title":"Expert consensus document: consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer","volume":"12","author":"Kamat","year":"2015","journal-title":"Nat Rev Urol"},{"issue":"1","key":"10.1016\/j.purol.2020.03.005_bib0390","article-title":"Bacillus Calmette-Gu\u00e9rin unresponsiveness in non-muscle-invasive bladder cancer patients: what the urologists should know","volume":"71","author":"Moschini","year":"2019","journal-title":"Minerva Urol e Nefrol"},{"issue":"19","key":"10.1016\/j.purol.2020.03.005_bib0395","first-page":"4912","article-title":"Electromotive versus passive diffusion of mitomycin C into human bladder wall: concentration-depth profiles studies","volume":"59","author":"Di Stasi","year":"1999","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.purol.2020.03.005_bib0400","first-page":"875","article-title":"Electromotive delivery of mitomycin C into human bladder wall","volume":"57","author":"Di Stasi","year":"1997","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.purol.2020.03.005_bib0405","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S1470-2045(11)70190-5","article-title":"Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial","volume":"12","author":"Di Stasi","year":"2011","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.purol.2020.03.005_bib0410","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1159\/000502663","article-title":"Intravesical treatment with electro-mediated administration of mytomicin C as prophylaxis for intermediate and high-risk non-muscle-invasive bladder cancer: a retrospective multicenter study","volume":"103","author":"Carando","year":"2019","journal-title":"Urol Int"},{"issue":"1","key":"10.1016\/j.purol.2020.03.005_bib0415","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1186\/s12885-018-5134-7","article-title":"ElectroMotive drug administration (EMDA) of mitomycin C as first-line salvage therapy in high risk \u201cBCG failure\u201d non-muscle invasive bladder cancer: 3 years follow-up outcomes","volume":"18","author":"Racioppi","year":"2018","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.purol.2020.03.005_bib0420","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/j.juro.2016.01.103","article-title":"Sequential bacillus Calmette-Gu\u00e9rin\/electromotive drug administration of mitomycin C as the standard intravesical regimen in high-risk non-muscle invasive bladder cancer: 2-year outcomes","volume":"195","author":"Gan","year":"2016","journal-title":"J Urol"},{"issue":"11","key":"10.1016\/j.purol.2020.03.005_bib0425","doi-asserted-by":"crossref","DOI":"10.1038\/nrurol.2017.125","article-title":"Characteristics and clinical significance of histological variants of bladder cancer","volume":"14","author":"Moschini","year":"2017","journal-title":"Nat Rev Urol"},{"issue":"6","key":"10.1016\/j.purol.2020.03.005_bib0430","first-page":"649","article-title":"Incidence and effect of variant histology on oncological outcomes in patients with bladder cancer treated with radical cystectomy","volume":"35","author":"Moschini","year":"2017","journal-title":"Urol Oncol Semin Orig Investig [Internet]"},{"issue":"4","key":"10.1016\/j.purol.2020.03.005_bib0435","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.eururo.2018.11.052","article-title":"Micropapillary urothelial carcinoma of the bladder: a systematic review and meta-analysis of disease characteristics and treatment outcomes","volume":"75","author":"Abufaraj","year":"2019","journal-title":"Eur Urol"},{"issue":"10","key":"10.1016\/j.purol.2020.03.005_bib0440","doi-asserted-by":"crossref","DOI":"10.1007\/s00345-015-1482-y","article-title":"Fifteen-year single-centre experience with three different surgical procedures of nerve-sparing cystectomy in selected organ-confined bladder cancer patients","volume":"33","author":"Colombo","year":"2015","journal-title":"World J Urol"}],"container-title":["Progr\u00e8s en Urologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S116670872030097X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S116670872030097X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T06:32:38Z","timestamp":1761114758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S116670872030097X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S116670872030097X"],"URL":"https:\/\/doi.org\/10.1016\/j.purol.2020.03.005","relation":{},"ISSN":["1166-7087"],"issn-type":[{"type":"print","value":"1166-7087"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of device-assisted therapies in the management of non-muscle invasive bladder cancer: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Progr\u00e8s en Urologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.purol.2020.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}